Literature DB >> 16331092

New-onset diabetes and antihypertensive drugs.

Giuseppe Mancia1, Guido Grassi, Alberto Zanchetti.   

Abstract

Observational studies have provided evidence that a consistent fraction (approximately 15-20%) of hypertensive patients displays a glucose intolerance state that may be aggravated by antihypertensive drug regimens based on thiazide diuretics or beta-blockers. This review examines the relative and absolute diabetogenic effects of antihypertensive drugs, by comparing the impact of 'new' (calcium antagonists, angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists) versus 'old' (diuretics and beta-blockers) drugs on new-onset diabetes in recent clinical trials. Evidence is provided that compared with diuretics and beta-blockers, new-onset diabetes is less common with 'new' drugs, and that conventional antihypertensive compounds, particularly when combined together, may amplify the natural time-dependent tendency towards the development of this metabolic disease. This paper provides new insights into the potential mechanisms responsible for the phenomenon and the clinical significance of antihypertensive drug-induced diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16331092     DOI: 10.1097/01.hjh.0000194119.42722.21

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  50 in total

Review 1.  Prediabetes and cardiovascular risk in hypertensive patients.

Authors:  Julian Segura; Cecilia Roldán; Jose A García-Donaire; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

Review 2.  Metabolic safety of antihypertensive drugs: myth versus reality.

Authors:  Sameer Stas; Lama Appesh; James Sowers
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

3.  Hypertension with metabolic syndrome: think thiazides are old hat? ALLHAT says think again.

Authors:  Michael D Mendoza; James J Stevermer
Journal:  J Fam Pract       Date:  2008-05       Impact factor: 0.493

4.  Increased C-reactive protein is associated with future development of diabetes mellitus in essential hypertensive patients.

Authors:  Chiung-Mei Weng; Chang-Hua Chou; Yao-Yi Huang; Chih-Chan Lin; Yen-Wen Liu; Wei-Chuan Tsai
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

5.  Cardiovascular endocrinology: tailoring antihypertensive drug treatment to body size.

Authors:  Guido Grassi; Giuseppe Mancia
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

6.  2008 white paper for implementing strategies and interventions for cardiovascular prevention in Italy.

Authors:  Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-03

Review 7.  Type 2 Diabetes and Thiazide Diuretics.

Authors:  André J Scheen
Journal:  Curr Diab Rep       Date:  2018-02-05       Impact factor: 4.810

8.  [European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish Adaptation].

Authors:  José M A Lobos Bejarano; Miguel Angel Royo-Bordonada; Carlos Brotons; Luís Alvarez-Sala; Pedro Armario; Antonio Maiques; Dídac Mauricio; Susana Sans; Fernando Villar; Angel Lizcano; Antonio Gil-Núñez; Fernando de Alvaro; Pedro Conthe; Emilio Luengo; Alfonso Del Río; Olga Cortés; Ana de Santiago; Miguel A Vargas; Mercedes Martínez; Vicenta Lizarbe
Journal:  Aten Primaria       Date:  2009-07-15       Impact factor: 1.137

Review 9.  Rational use of antihypertensive medications in children.

Authors:  Michael A Ferguson; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2013-05-29       Impact factor: 3.714

Review 10.  Antihypertensive therapy, new-onset diabetes, and cardiovascular disease.

Authors:  J N Basile
Journal:  Int J Clin Pract       Date:  2009-02-09       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.